Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin

Thrombosis Research

Volumn 136, Issue 3, 2015, Pages 658-662

  Furugohri, Taketoshi ^a   Morishima, Yoshiyuki ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Activated protein C; Direct factor Xa inhibitor; Direct thrombin inhibitor; Edoxaban; Intrinsic pathway; Melagatran

Indexed keywords

EDOXABAN; HEPARIN; KAOLIN; MELAGATRAN; PROTEIN C; THROMBOMODULIN; ANTICOAGULANT AGENT; ANTITHROMBIN; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; THROMBIN; THROMBOPLASTIN;

ABSORPTION LAG TIME; ARTICLE; CALIBRATED AUTOMATED THROMBOGRAPHY; CONTROLLED STUDY; ENDOGENOUS THROMBIN POTENTIAL; FUNCTIONS OF THE HEMIC, LYMPHATIC AND RETICULOENDOTHELIAL SYSTEMS; HEMATOLOGICAL PARAMETERS; HEMATOLOGICAL PROCEDURE; HUMAN; INTRINSIC PATHWAY; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; THROMBIN GENERATION; BIOSYNTHESIS; BLOOD CLOTTING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY;

ANTICOAGULANTS; ANTITHROMBINS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FACTOR XA INHIBITORS; HEPARIN; HUMANS; PYRIDINES; THIAZOLES; THROMBIN; THROMBOPLASTIN;

EID: 84940182978     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.06.034     Document Type: Article

References (31)

1. T. Furugohri, Y. Shiozaki, S. Muramatsu, Y. Honda, C. Matsumoto, K. Isobe, and N. Sugiyama Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models Eur. J. Pharmacol. 514 2005 35 42
2. T. Furugohri, N. Sugiyama, Y. Morishima, and T. Shibano Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system Thromb. Haemost. 106 2011 1076 1083
3. T. Furugohri, T. Fukuda, N. Tsuji, A. Kita, Y. Morishima, and T. Shibano Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats Eur. J. Pharmacol. 686 2012 74 80
4. E. Perzborn, S. Heitmeier, U. Buetehorn, and V. Laux Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo J. Thromb. Haemost. 12 2014 1054 1065
5. O.D. Ratnoff, and J.E. Colopy A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma J. Clin. Investig. 34 1955 602 613
6. T. Renné, M. Pozgajová, S. Grüner, K. Schuh, H.U. Pauer, P. Burfeind, D. Gailani, and B. Nieswandt Defective thrombus formation in mice lacking coagulation factor XII J. Exp. Med. 202 2005 271 281
7. F. Zito, F. Drummond, S.R. Bujac, M.P. Esnouf, J.H. Morrissey, S.E. Humphries, and G.J. Miller Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men Circulation 102 2000 2058 2062
8. H. Grundt, D.W. Nilsen, O. Hetland, E. Valente, and H.E. Fagertun Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction Am. Heart J. 147 2004 260 266
9. E.D. Rosen, D. Gailani, and F.J. Castellino FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse Thromb. Haemost. 87 2002 774 776
10. H.C. Hemker, P. Giesen, R. AlDieri, V. Regnault, E. de Smed, R. Wagenvoord, T. Lecompte, and S. Béguin The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability Pathophysiol. Haemost. Thromb. 32 2002 249 253
11. F. Trento, F. Cattaneo, R. Pescador, R. Porta, and L. Ferro Antithrombin activity of an algal polysaccharide Thromb. Res. 102 2001 457 465
12. N. Boknäs, L. Faxälv, T.L. Lindahl, and S. Ramström Contact activation: important to consider when measuring the contribution of tissue factor-bearing microparticles to thrombin generation using phospholipid-containing reagents J. Thromb. Haemost. 12 2014 515 518
13. E.D. Rosen, J.C. Chan, E. Idusogie, F. Clotman, G. Vlasuk, T. Luther, L.R. Jalbert, S. Albrecht, L. Zhong, A. Lissens, L. Schoonjans, L. Moons, D. Collen, F.J. Castellino, and P. Carmeliet Mice lacking factor VII develop normally but suffer fatal perinatal bleeding Nature 390 1997 290 294
14. T.H. Bugge, Q. Xiao, K.W. Kombrinck, M.J. Flick, K. Holmbäck, M.J. Danton, M.C. Colbert, D.P. Witte, K. Fujikawa, E.W. Davie, and J.L. Degen Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation Proc. Natl. Acad. Sci. U. S. A. 93 1996 6258 6263
15. J. Steffel, T.F. Lüscher, and F.C. Tanner Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications Circulation 113 2006 722 731
16. N. Mackman, R.E. Tilley, and N.S. Key Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis Arterioscler. Thromb. Vasc. Biol. 27 2007 1687 1693
17. J.I. Weitz, J. Hirsh, and M.M. Samama New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl. 2004 265S 266S
18. B.N. Bouma, P.A. von dem Borne, and J.C. Meijers Factor XI and protection of the fibrin clot against lysis-a role for the intrinsic pathway of coagulation in fibrinolysis Thromb. Haemost. 80 1998 24 27
19. D. Gailani, and T. Renné The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J. Thromb. Haemost. 5 2007 1106 1112
20. D. Gailani, and T. Renné Intrinsic pathway of coagulation and arterial thrombosis Arterioscler. Thromb. Vasc. Biol. 27 2007 2507 2513
21. E.C. Löwenberg, J.C. Meijers, B.P. Monia, and M. Levi Coagulation factor XI as a novel target for antithrombotic treatment J. Thromb. Haemost. 8 2010 2349 2357
22. G.J. Miller, M.P. Esnouf, A.I. Burgess, J.A. Cooper, and J.P. Mitchell Risk of coronary heart disease and activation of factor XII in middle-aged men Arterioscler. Thromb. Vasc. Biol. 17 1997 2103 2106
23. B. Siegerink, J.W. Govers-Riemslag, F.R. Rosendaal, H. Ten Cate, and A. Algra Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study Circulation 122 2010 1854 1861
24. J. Meijers, W. Tekelenburg, B. Bouma, R. Bertina, and F. Rosendaal High levels of coagulation factor XI as a risk factor for venous thrombosis N. Engl. J. Med. 342 2000 696 701
25. O. Salomon, D.M. Steinberg, N. Koren-Morag, D. Tanne, and U. Seligsohn Reduced incidence of ischemic stroke in patients with severe factor XI deficiency Blood 111 2008 4113 4117
26. W.M. Halbmayer, A. Haushofer, R. Schön, C. Mannhalter, E. Strohmer, K. Baumgarten, and M. Fischer The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors Thromb. Haemost. 71 1994 68 72
27. Food and Drug Administration Exanta (Ximelagatran). Integrated executive summary of FDA review for NDA 2004 21 686
28. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, L. Wallentin, and RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
29. S.H. Hohnloser, J. Oldgren, S. Yang, L. Wallentin, M. Ezekowitz, P. Reilly, J. Eikelboom, M. Brueckmann, S. Yusuf, and S.J. Connolly Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial Circulation 125 2012 669 676
30. J. Douxfils, F. Buckinx, F. Mullier, V. Minet, V. Rabenda, J.Y. Reginster, P. Hainaut, O. Bruyère, and J.M. Dogné Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials J. Am. Heart Assoc. 3 2014 e000515
31. J.W. Eikelboom, S.J. Connolly, M. Brueckmann, C.B. Granger, A.P. Kappetein, M.J. Mack, J. Blatchford, K. Devenny, J. Friedman, K. Guiver, R. Harper, Y. Khder, M.T. Lobmeyer, H. Maas, J.U. Voigt, M.L. Simoons, F. Van de Werf, and RE-ALIGN Investigators Dabigatran versus warfarin in patients with mechanical heart valves N. Engl. J. Med. 369 2013 1206 1214